The Startup Incubation and Innovation Centre (SIIC), the technology business incubator of the Indian Institute of Technology Kanpur (IITK), has entered into an agreement with Boehringer Ingelheim India, a global pharmaceutical company, to foster healthcare innovation.

Boehringer Ingelheim has pledged a grant to support Manastik Technologies, a SIIC-incubated startup focused on developing a tele-neurorehabilitation app for multidisciplinary dementia care and diagnosis, focusing on the unmet need for comprehensive mental health strategies to address the growing burden of dementia and other mental health disorders in India.

Using DADT technology (Dementia Application and Diagnosis & Tracking), Manastik caters to the dementia ecosystem by providing those in need with personalized help curated by experienced doctors and neuro healthcare professionals. Boehringer pledged the grant to Manastik to validate their app, raise awareness, and conduct dementia screening campaigns nationwide in India.

Highlighting the significance of this partnership, Gagandeep Singh Bedi, Managing Director, Boehringer Ingelheim India, said, “Our second collaboration with IIT Kanpur reinforces our belief in the power of collective innovation. We bring together scientific communities, patients and healthcare systems to develop new, holistic, and sustainable breakthrough therapies that address healthcare’s greatest challenges. With every innovation, we are not just advancing science, but also redefining the possibilities for patient care, aiming for a future where everyone has access to the best treatments and health outcomes.”

Prof. Ankush Sharma, Professor In Charge, SIIC, emphasized the far-reaching effect of this support stating, “SIIC is home to medical technologies with a strong social impact. Boehringer Ingelheim’s support aligns perfectly with our vision to create a healthy India for all. It enables us to empower the startup community, fostering an ecosystem of innovation and collaboration. Together, we are not just dreaming of a better future, we are actively building it.”

The longstanding relationship between Boehringer Ingelheim and SIIC emphasizes their shared vision of promoting socially beneficial technologies.